{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:48:10Z","timestamp":1789184890598,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR-MR1\\u20132022\\u201312,376,879"],"award-info":[{"award-number":["PNRR-MR1\\u20132022\\u201312,376,879"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP I53C22001440006"],"award-info":[{"award-number":["CUP I53C22001440006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vph.2024.107442","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:37:35Z","timestamp":1732034255000},"page":"107442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Sotatercept: New drug on the horizon of pulmonary hypertension"],"prefix":"10.1016","volume":"157","author":[{"given":"Rosalinda","family":"Madonna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vph.2024.107442_bb0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.vph.2024.107442_bb0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.vph.2024.107442_bb0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/cvr\/cvr232","article-title":"Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress","volume":"92","author":"Jerkic","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.vph.2024.107442_bb0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation","volume":"181","author":"Girerd","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.vph.2024.107442_bb0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/rp.56.1.417","article-title":"Mechanisms of inhibin signal transduction","volume":"56","author":"Bernard","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.vph.2024.107442_bb0030","first-page":"1","article-title":"Chemical and biological characterization of the inhibin family of protein hormones","volume":"44","author":"Vale","year":"1988","journal-title":"Recent Prog. Horm. Res."},{"issue":"12","key":"10.1016\/j.vph.2024.107442_bb0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1210\/mend-2-12-1352","article-title":"Rapid changes in the expression of inhibin alpha-, beta A-, and beta B-subunits in ovarian cell types during the rat estrous cycle","volume":"2","author":"Meunier","year":"1988","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.vph.2024.107442_bb0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/cvr\/cvm097","article-title":"Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae","volume":"77","author":"Santibanez","year":"2008","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.vph.2024.107442_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.preghy.2015.09.006","article-title":"Effects of normal and high circulating concentrations of activin a on vascular endothelial cell functions and vasoactive factor production","volume":"5","author":"Yong","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.vph.2024.107442_bb0050","doi-asserted-by":"crossref","first-page":"648981","DOI":"10.3389\/fcvm.2021.648981","article-title":"Endothelin-1 upregulates Activin receptor-like Kinase-1 expression via G<i>i<\/i>\/RhoA\/Sp-1\/rho kinase pathways in human pulmonary arterial endothelial cells","volume":"8","author":"Sugimoto","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"543","key":"10.1016\/j.vph.2024.107442_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.vph.2024.107442_bb0060","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.vph.2024.107442_bb0065","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","article-title":"A selective transforming growth factor-\u03b2 ligand trap attenuates pulmonary hypertension","volume":"194","author":"Yung","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2353\/ajpath.2009.080565","volume":"174","author":"Thomas","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.vph.2024.107442_bb0075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200707-1083OC","article-title":"Role of the TGF-beta\/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension","volume":"177","author":"Zaiman","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/archneur.1988.00520260102029","article-title":"Homozygous protein C deficiency in a newborn. Clinicopathologic correlation","volume":"45","author":"Tarras","year":"1988","journal-title":"Arch Neurol."},{"issue":"24","key":"10.1016\/j.vph.2024.107442_bb0085","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles of the Activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.vph.2024.107442_bb0090","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"PULSAR Trial Investigators. Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.vph.2024.107442_bb0095","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.vph.2024.107442_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of Sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ. Heart Fail."},{"issue":"3","key":"10.1016\/j.vph.2024.107442_bb0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/cpt.3116","article-title":"The impact of immunogenicity on the pharmacokinetics, efficacy, and safety of Sotatercept in a phase III study of pulmonary arterial hypertension","volume":"115","author":"Liao","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.vph.2024.107442_bb0110","doi-asserted-by":"crossref","first-page":"2301107","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.vph.2024.107442_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.preghy.2015.09.006","article-title":"Effects of normal and high circulating concentrations of activin a on vascular endothelial cell functions and vasoactive factor production","volume":"5","author":"Yong","year":"2015","journal-title":"Pregnancy Hypertens."},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.preghy.2016.03.001","article-title":"Role of activin a in the pathogenesis of endothelial cell dysfunction in preeclampsia","volume":"6","author":"Hobson","year":"2016","journal-title":"Pregnancy Hypertens."},{"issue":"5","key":"10.1016\/j.vph.2024.107442_bb0125","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1210\/endo-129-5-2355","article-title":"Transforming growth factor-beta: role in mediating serum-induced endothelin production by vascular endothelial cells","volume":"129","author":"Brown","year":"1991","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.vph.2024.107442_bb0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mvr.2010.05.010","article-title":"Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension","volume":"80","author":"Star","year":"2010","journal-title":"Microvasc. Res."},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2009.02.007","article-title":"Activin and related proteins in inflammation: not just interested bystanders","volume":"20","author":"Phillips","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.vph.2024.107442_bb0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mvr.2012.10.012","article-title":"ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells","volume":"85","author":"Star","year":"2013","journal-title":"Microvasc. Res."},{"issue":"12","key":"10.1016\/j.vph.2024.107442_bb0145","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.vph.2024.107442_bb0150","first-page":"00326","article-title":"Pulmonary hypertension associated to left heart disease: phenotypes and treatment","volume":"S0953-6205","author":"Madonna","year":"2024","journal-title":"Eur. J. Intern. Med."},{"issue":"38","key":"10.1016\/j.vph.2024.107442_bb0155","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"482","key":"10.1016\/j.vph.2024.107442_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau8680","article-title":"Activin type II receptor signaling in cardiac aging and heart failure","volume":"11","author":"Roh","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/ijms18020374","article-title":"Effects of the Activin A-Follistatin system on myocardial cell apoptosis through the endoplasmic reticulum stress pathway in heart failure","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.vph.2024.107442_bb0170","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/01.CIR.0000120704.97934.41","article-title":"Elevated levels of activin a in heart failure: potential role in myocardial remodeling","volume":"109","author":"Yndestad","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vph.2024.107442_bb0175","doi-asserted-by":"crossref","first-page":"H1415","DOI":"10.1152\/ajpheart.01048.2009","article-title":"Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction","volume":"298","author":"Tan","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"38","key":"10.1016\/j.vph.2024.107442_bb0180","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.vph.2024.107442_bb0185","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vph.2024.107442_bb0190","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.664","article-title":"Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction","volume":"19","author":"Ghio","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/j.vph.2024.107442_bb0195","doi-asserted-by":"crossref","first-page":"L841","DOI":"10.1152\/ajplung.00158.2005","article-title":"BMP signaling controls PASMC KV channel expression in vitro and in vivo","volume":"290","author":"Young","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"5","key":"10.1016\/j.vph.2024.107442_bb0200","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1165\/rcmb.2021-0549ED","article-title":"Targeting ATP-sensitive K<sup>+<\/sup> channels to treat pulmonary hypertension","volume":"66","author":"Breen","year":"2022","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"10.1016\/j.vph.2024.107442_bb0205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/biom12101341","article-title":"Potassium channels as therapeutic targets in pulmonary arterial hypertension","volume":"12","author":"Redel-Traub","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.vph.2024.107442_bb0210","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.vph.2024.107442_bb0215","first-page":"2660","article-title":"Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study","volume":"109","author":"Bose","year":"2024","journal-title":"Haematologica"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912400168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912400168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:07:23Z","timestamp":1778818043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912400168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":43,"alternative-id":["S153718912400168X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2024.107442","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotatercept: New drug on the horizon of pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2024.107442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107442"}}